Updated Jul 16, 2026
PAKOLA STEVE has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $940K.
Steve Pakola is a corporate executive known for his role at REGENXBIO Inc., a biotechnology company focused on gene therapy. He has been involved in various leadership capacities within the company, contributing to its strategic direction and operational management.
| Role | Insider |
|---|---|
| Notability | 60/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | RGNX | REGENXBIO Inc. | S — Open-market sale | 2.2K | $13.64 | $29K |
| 2026-07-06 | RGNX | REGENXBIO Inc. | M — Option exercise | 2.2K | $7.86 | $17K |
| 2026-07-02 | RGNX | REGENXBIO Inc. | S — Open-market sale | 36.7K | $12.86 | $472K |
| 2026-07-02 | RGNX | REGENXBIO Inc. | M — Option exercise | 36.7K | $7.86 | $289K |
| 2026-07-02 | RGNX | REGENXBIO Inc. | S — Open-market sale | 19.6K | $11.04 | $216K |
| 2026-05-13 | RGNX | REGENXBIO Inc. | S — Open-market sale | 15.3K | $11.02 | $169K |
| 2026-03-12 | RGNX | REGENXBIO Inc. | S — Open-market sale [10b5-1] | 5.1K | $10.35 | $53K |
| 2026-02-03 | RGNX | REGENXBIO Inc. | F — Tax withholding / forfeiture | 5.3K | $11.16 | $59K |
Steve Pakola is a corporate executive known for his role at REGENXBIO Inc., a biotechnology company focused on gene therapy. He has been involved in various leadership capacities within the company, contributing to its strategic direction and operational management.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($940K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live PAKOLA STEVE profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.